Werewolf Therapeutics, Inc.

NasdaqGS:HOWL Stok Raporu

Piyasa değeri: US$16.5m

Werewolf Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Dan Hicklin

İcra Kurulu Başkanı

US$1.6m

Toplam tazminat

CEO maaş yüzdesi39.63%
CEO görev süresi8.8yrs
CEO sahipliği1.3%
Yönetim ortalama görev süresiVeri yok
Yönetim Kurulu ortalama görev süresi6.7yrs

Son yönetim güncellemeleri

Recent updates

Analiz Makalesi • May 14

Here's Why We're A Bit Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analiz Makalesi • Nov 14

Werewolf Therapeutics (NASDAQ:HOWL) Has Debt But No Earnings; Should You Worry?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analiz Makalesi • Jul 31

Is Werewolf Therapeutics (NASDAQ:HOWL) Using Debt Sensibly?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Seeking Alpha • Jul 01

Werewolf Therapeutics: Continuing To Advance And Show More Promise In Phase 1

Summary Werewolf Therapeutics, Inc. is an early-stage biotech focusing on cytokine therapy for cancer treatment. The Pipeline update includes positive results for WTX-124 in clinical trials and promising data for WTX-330. Financially, the company has a decent cash position for now, but may need to address cash burn rate in the near future. Read the full article on Seeking Alpha
Analiz Makalesi • Jun 04

Some Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shareholders Look For Exit As Shares Take 34% Pounding

Unfortunately for some shareholders, the Werewolf Therapeutics, Inc. ( NASDAQ:HOWL ) share price has dived 34% in the...
Seeking Alpha • Apr 04

Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space

Summary Werewolf Therapeutics, Inc. develops modified cytokines for cancer treatment, including WTX-124, a modified IL-2, and WTX-330, a modified IL-12. Xilio Therapeutics out-licensed their modified IL-12 to Gilead, but I wouldn't be surprised if Werewolf Therapeutics also has a competitive modified IL-12, with WTX-330. Werewolf Therapeutics is reporting data from its clinical trials of WTX-124 and WTX-330 this half (H1'24), providing near-term catalysts. Read the full article on Seeking Alpha
Analiz Makalesi • Feb 07

Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Werewolf Therapeutics, Inc. ( NASDAQ:HOWL ) shares have continued their recent momentum with a 27% gain in the last...
Analiz Makalesi • Jan 19

Is Werewolf Therapeutics (NASDAQ:HOWL) A Risky Investment?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analiz Makalesi • Dec 09

There's No Escaping Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Muted Revenues Despite A 28% Share Price Rise

Werewolf Therapeutics, Inc. ( NASDAQ:HOWL ) shares have had a really impressive month, gaining 28% after a shaky period...
Analiz Makalesi • Sep 30

Analysts Just Shipped A Captivating Upgrade To Their Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Estimates

Werewolf Therapeutics, Inc. ( NASDAQ:HOWL ) shareholders will have a reason to smile today, with the analysts making...
Analiz Makalesi • Aug 13

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Werewolf Therapeutics, Inc. ( NASDAQ:HOWL ) just released its latest second-quarter results and things are looking...
Analiz Makalesi • May 06

We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analiz Makalesi • Jan 27

Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analiz Makalesi • Oct 24

We're Not Very Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analiz Makalesi • Jul 08

We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analiz Makalesi • Mar 24

Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analiz Makalesi • Dec 09

Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although...

CEO Tazminat Analizi

Dan Hicklin'un ücretlendirmesi Werewolf Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Mar 31 2026n/an/a

-US$56m

Dec 31 2025US$2mUS$633k

-US$61m

Sep 30 2025n/an/a

-US$73m

Jun 30 2025n/an/a

-US$73m

Mar 31 2025n/an/a

-US$72m

Dec 31 2024US$3mUS$608k

-US$71m

Sep 30 2024n/an/a

-US$62m

Jun 30 2024n/an/a

-US$54m

Mar 31 2024n/an/a

-US$42m

Dec 31 2023US$1mUS$583k

-US$37m

Sep 30 2023n/an/a

-US$37m

Jun 30 2023n/an/a

-US$41m

Mar 31 2023n/an/a

-US$50m

Dec 31 2022US$2mUS$530k

-US$54m

Sep 30 2022n/an/a

-US$60m

Jun 30 2022n/an/a

-US$62m

Mar 31 2022n/an/a

-US$115m

Dec 31 2021US$2mUS$498k

-US$202m

Sep 30 2021n/an/a

-US$205m

Jun 30 2021n/an/a

-US$197m

Mar 31 2021n/an/a

-US$127m

Dec 31 2020US$3mUS$425k

-US$28m

Tazminat ve Piyasa: Dan 'nin toplam tazminatı ($USD 1.60M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 658.93K ).

Tazminat ve Kazançlar: Dan 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Dan Hicklin (62 yo)

8.8yrs
Görev süresi
US$1,596,355
Tazminat

Dr. Daniel J. Hicklin, also known as Dan, Ph D., Founded Werewolf Therapeutics, Inc. in October 2017 and has been its President and Chief Executive Officer since August 2019. He serves on its Board of Dire...

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Daniel Hicklin
Founder8.8yrsUS$1.60m1.33%
$ 219.7k
Luke Evnin
Independent Chairman of the Board8.8yrsUS$88.69kVeri yok
Michael Sherman
Independent Director5.2yrsUS$71.44k0%
$ 0
Anil Singhal
Independent Director1.4yrsUS$95.32kVeri yok
Charles Craik
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Vijay Kuchroo
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Briggs Duncan W. Morrison
Director6.7yrsUS$56.44k0.032%
$ 5.3k
Karl Wittrup
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Michael Atkins
Member of Scientific Advisory Board & Independent Director7.9yrsUS$111.94k0.030%
$ 4.9k
Meeta Chatterjee
Independent Director4.8yrsUS$63.19k0%
$ 0
Dario Vignali
Member of Scientific Advisory Boardno dataVeri yokVeri yok
6.7yrs
Ortalama Görev Süresi
68yo
Ortalama Yaş

Deneyimli Yönetim Kurulu: HOWL 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.7 yıldır).

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/07/16 01:57
Gün Sonu Hisse Fiyatı2026/07/16 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Werewolf Therapeutics, Inc. 6 Bu analistlerden 1, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Jason ZemanskyBofA Global Research
Maneka MirchandaneyEvercore ISI
Christopher HowertonJefferies LLC